Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain

Diabetes, Obesity and Metabolism

Volumn 12, Issue 6, 2010, Pages 545-547

  Belanoff, J K ^a   Blasey, C M ^a,b   Clark, R D ^a   Roe, R L ^a  

^a Corcept Therapeutics Incorporated ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Antipsychotics; Glucocorticoids; Mifepristone; Olanzapine; Olanzapine induced weight gain

Indexed keywords

CORT 108297; GLUCOCORTICOID RECEPTOR ANTAGONIST; OLANZAPINE; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; NONHUMAN; RAT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77953220891     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01185.x     Document Type: Article

References (12)

1. Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
2. Barnett AH, Mackin P, Chaudhry I. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. (Perspective). J Psychopharmacol 2007, 21:357-373. July;
3. Marder SR, Essock SM, Miller AL. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349. Aug;
4. Baptista T, De Mendoza S, Beaulieu S, Bermudez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord 2004, 2:290-307.
5. Holt R, Peveler R. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009, 11:665-679.
6. Koro CE, Fedder DO, L'Italien GL. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002, 325:243-249.
7. Reaven GM, Lieberman JA, Sethuraman G. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 2009, 43:997-1002. Jul;
8. Beebe KL, Block T, Debattista C. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res 2006, 171:225-229.
9. Gross C, Blasey C, Roe R. Mifepristone treatment of olanzapine induced weight gain in healthy men. Adv Ther 2009, 26(10):959-969.
10. Belanoff J. Mifepristone reduces weight gain associated with risperidone use. 2009, Poster presented at 40th Annual ISPNE; July, San Francisco, California
11. Clark RD, Ray NC, Williams K. 1H-Pyrazolo [3,4-g] hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg Med Chem Lett 2008, 18:1312-1317. Feb 15;
12. Asagami T, Clark R, Belanoff J, Tsao P. A new selective glucocorticoid antagonist suppresses body weight gain as well as improves insulin sensitivity. 2009, Abstract presented at the Annual Meeting of the American Diabetes Association;, New Orleans, LA